Advanced development of nitazoxanide, administered alone or in combination with oseltamivir, for treatment of acute uncomplicated influenza virus infection in adults and pediatric patients at least 12…
Ended Definitive Contract Awarded Last action
- Contract number
- HHSO100201300004C
- Awardee
-
Romark Laboratories, L.C. UEI GJA6RDFXCEJ3
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $70,748,205
Award facts
- Opportunity
- Contract value 100% obligated
- $70,748,204.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 6 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Tampa, FL 33607, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$4,353,830 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $29,009,884 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $1,999,697 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $44,092,454 |
Show all 11
About this award
The U.S. Department of Health and Human Services (HHS), through the Office of the Assistant Secretary for Preparedness and Response, awarded a $70,748,204.88 cost-plus-fixed-fee contract to Romark Laboratories, L.C. for the advanced development of nitazoxanide, administered alone or in combination with oseltamivir, for the treatment of acute uncomplicated influenza virus infection in adults and pediatric patients at least 12 years of age. The contract has a completion date of December 31, 2015 and was awarded on February 28, 2013. This contract is not set-aside.
Description
Advanced development of nitazoxanide, administered alone or in combination with oseltamivir, for treatment of acute uncomplicated influenza virus infection in adults and pediatric patients at least 12 years of age
Quick answers
Who was awarded contract HHSO100201300004C?
HHSO100201300004C was awarded to Romark Laboratories, L.C. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on February 28, 2013.
How much is contract HHSO100201300004C worth?
The government has obligated $70,748,205 on HHSO100201300004C.
Was contract HHSO100201300004C competed?
The extent of competition for HHSO100201300004C was full and open competition. The government received 6 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award